473 related articles for article (PubMed ID: 31015438)
1. BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors.
Wang X; Wang S; Troisi EC; Howard TP; Haswell JR; Wolf BK; Hawk WH; Ramos P; Oberlick EM; Tzvetkov EP; Ross A; Vazquez F; Hahn WC; Park PJ; Roberts CWM
Nat Commun; 2019 Apr; 10(1):1881. PubMed ID: 31015438
[TBL] [Abstract][Full Text] [Related]
2. SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation.
Wang X; Lee RS; Alver BH; Haswell JR; Wang S; Mieczkowski J; Drier Y; Gillespie SM; Archer TC; Wu JN; Tzvetkov EP; Troisi EC; Pomeroy SL; Biegel JA; Tolstorukov MY; Bernstein BE; Park PJ; Roberts CW
Nat Genet; 2017 Feb; 49(2):289-295. PubMed ID: 27941797
[TBL] [Abstract][Full Text] [Related]
3. SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters.
Nakayama RT; Pulice JL; Valencia AM; McBride MJ; McKenzie ZM; Gillespie MA; Ku WL; Teng M; Cui K; Williams RT; Cassel SH; Qing H; Widmer CJ; Demetri GD; Irizarry RA; Zhao K; Ranish JA; Kadoch C
Nat Genet; 2017 Nov; 49(11):1613-1623. PubMed ID: 28945250
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth.
Kim KH; Roberts CW
Cancer Genet; 2014 Sep; 207(9):365-72. PubMed ID: 24853101
[TBL] [Abstract][Full Text] [Related]
5. Tumor suppressor SMARCB1 suppresses super-enhancers to govern hESC lineage determination.
Langer LF; Ward JM; Archer TK
Elife; 2019 Apr; 8():. PubMed ID: 31033435
[TBL] [Abstract][Full Text] [Related]
6. BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors.
Krämer KF; Moreno N; Frühwald MC; Kerl K
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28714904
[TBL] [Abstract][Full Text] [Related]
7. BAFfling pathologies: Alterations of BAF complexes in cancer.
Arnaud O; Le Loarer F; Tirode F
Cancer Lett; 2018 Apr; 419():266-279. PubMed ID: 29374542
[TBL] [Abstract][Full Text] [Related]
8. NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition.
Drosos Y; Myers JA; Xu B; Mathias KM; Beane EC; Radko-Juettner S; Mobley RJ; Larsen ME; Piccioni F; Ma X; Low J; Hansen BS; Peters ST; Bhanu NV; Dhanda SK; Chen T; Upadhyaya SA; Pruett-Miller SM; Root DE; Garcia BA; Partridge JF; Roberts CWM
Mol Cell; 2022 Jul; 82(13):2472-2489.e8. PubMed ID: 35537449
[TBL] [Abstract][Full Text] [Related]
9. Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF.
Radko-Juettner S; Yue H; Myers JA; Carter RD; Robertson AN; Mittal P; Zhu Z; Hansen BS; Donovan KA; Hunkeler M; Rosikiewicz W; Wu Z; McReynolds MG; Roy Burman SS; Schmoker AM; Mageed N; Brown SA; Mobley RJ; Partridge JF; Stewart EA; Pruett-Miller SM; Nabet B; Peng J; Gray NS; Fischer ES; Roberts CWM
Nature; 2024 Apr; 628(8007):442-449. PubMed ID: 38538798
[TBL] [Abstract][Full Text] [Related]
10. SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.
Kuwahara Y; Wei D; Durand J; Weissman BE
Mol Cancer Res; 2013 Mar; 11(3):251-60. PubMed ID: 23364536
[TBL] [Abstract][Full Text] [Related]
11. A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation.
Michel BC; D'Avino AR; Cassel SH; Mashtalir N; McKenzie ZM; McBride MJ; Valencia AM; Zhou Q; Bocker M; Soares LMM; Pan J; Remillard DI; Lareau CA; Zullow HJ; Fortoul N; Gray NS; Bradner JE; Chan HM; Kadoch C
Nat Cell Biol; 2018 Dec; 20(12):1410-1420. PubMed ID: 30397315
[TBL] [Abstract][Full Text] [Related]
12. Recurrent SMARCB1 Mutations Reveal a Nucleosome Acidic Patch Interaction Site That Potentiates mSWI/SNF Complex Chromatin Remodeling.
Valencia AM; Collings CK; Dao HT; St Pierre R; Cheng YC; Huang J; Sun ZY; Seo HS; Mashtalir N; Comstock DE; Bolonduro O; Vangos NE; Yeoh ZC; Dornon MK; Hermawan C; Barrett L; Dhe-Paganon S; Woolf CJ; Muir TW; Kadoch C
Cell; 2019 Nov; 179(6):1342-1356.e23. PubMed ID: 31759698
[TBL] [Abstract][Full Text] [Related]
13. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.
Rao Q; Xia QY; Wang ZY; Li L; Shen Q; Shi SS; Wang X; Liu B; Wang YF; Shi QL; Ma HH; Lu ZF; He Y; Zhang RS; Yu B; Zhou XJ
Histopathology; 2015 Jul; 67(1):121-9. PubMed ID: 25496315
[TBL] [Abstract][Full Text] [Related]
14. SNF5/INI1 deficiency redefines chromatin remodeling complex composition during tumor development.
Wei D; Goldfarb D; Song S; Cannon C; Yan F; Sakellariou-Thompson D; Emanuele M; Major MB; Weissman BE; Kuwahara Y
Mol Cancer Res; 2014 Nov; 12(11):1574-85. PubMed ID: 25009291
[TBL] [Abstract][Full Text] [Related]
15. SWI/SNF complex heterogeneity is related to polyphenotypic differentiation, prognosis, and immune response in rhabdoid tumors.
Panwalkar P; Pratt D; Chung C; Dang D; Le P; Martinez D; Bayliss JM; Smith KS; Adam M; Potter S; Northcott PA; Mascarenhas L; Shows J; Pawel B; Margol A; Huang A; Judkins AR; Venneti S
Neuro Oncol; 2020 Jun; 22(6):785-796. PubMed ID: 31912158
[TBL] [Abstract][Full Text] [Related]
16. Rhabdoid tumors: an initial clue to the role of chromatin remodeling in cancer.
Lee RS; Roberts CW
Brain Pathol; 2013 Mar; 23(2):200-5. PubMed ID: 23432645
[TBL] [Abstract][Full Text] [Related]
17. Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells.
Darr J; Klochendler A; Isaac S; Geiger T; Eden A
Mol Cancer; 2015 Sep; 14():167. PubMed ID: 26370283
[TBL] [Abstract][Full Text] [Related]
18. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
Vangamudi B; Paul TA; Shah PK; Kost-Alimova M; Nottebaum L; Shi X; Zhan Y; Leo E; Mahadeshwar HS; Protopopov A; Futreal A; Tieu TN; Peoples M; Heffernan TP; Marszalek JR; Toniatti C; Petrocchi A; Verhelle D; Owen DR; Draetta G; Jones P; Palmer WS; Sharma S; Andersen JN
Cancer Res; 2015 Sep; 75(18):3865-3878. PubMed ID: 26139243
[TBL] [Abstract][Full Text] [Related]
19. Glioma tumor suppressor candidate region gene 1 (GLTSCR1) and its paralog GLTSCR1-like form SWI/SNF chromatin remodeling subcomplexes.
Alpsoy A; Dykhuizen EC
J Biol Chem; 2018 Mar; 293(11):3892-3903. PubMed ID: 29374058
[TBL] [Abstract][Full Text] [Related]
20. BRD9 Is a Critical Regulator of Androgen Receptor Signaling and Prostate Cancer Progression.
Alpsoy A; Utturkar SM; Carter BC; Dhiman A; Torregrosa-Allen SE; Currie MP; Elzey BD; Dykhuizen EC
Cancer Res; 2021 Feb; 81(4):820-833. PubMed ID: 33355184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
